Authors
Latest:
COVID-19: Risks for Pharma CommercializationIdentifying and acting on the risks developing in the major markets in light of COVID-19 disruption and the implications for assets in late-stage clinical development and early commercialization.
Latest:
COVID-19: Four Challenges for Issue Management TeamsDonna L. LaVoie discusses four key industry areas that will experience downstream pressures in the wake of the COVID-19 crisis.
Latest:
Sustaining Commercial Operations During a PandemicDan Schulman and Steve Trokenheim outline how life sciences companies can respond to the current crisis in measured ways to set them up for long-term success.
Latest:
End of Study Hacks: The New Digital AgeLearn from industry experts how to eliminate compliance risks associated with the up to 65% of sites that lose, never receive, or acknowledge these CDs/DVDs, along with the site audits where findings arise due to data access. Live: Thursday, May 7, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until May 7, 2021.
Latest:
The Power of Education in Treating Breast CancerBreast cancer is the most common cancer in women, and accounts for approximately 25% of all cancers in women worldwide.
Latest:
Field Perspective: A Collective View to inform the Future of Clinical ResearchTo really understand the issues and barriers preventing more efficient and effective clinical research, I went to the field to gather perspective from the core contributors.
Latest:
Quality More Important than Cost: Building the Business Case for PV AutomationAccording to new research, quality has overtaken cost as a priority in plans for automating adverse event reporting. John Price reveals the drivers and barriers to change.
Latest:
How Prepared Were Doctors for the COVID Digital Upswing?A new survey of healthcare professionals explores the pandemic-sparked shift in the adoption and acceptance of connected health technologies.
Latest:
How COVID-19 is Forcing Pharma to Adopt New Physician Interaction ModelsOver the coming months, HCPs and manufacturers will experiment with different approaches to e-detailing, in order to arrive at an approach that works for everyone, writes Scott Morano.
Latest:
COVID-19 and the Evolving Science of PharmacogenomicsInitial studies pointing to how genetic variations can impact disease states such as COVID-19 help to illustrate the growing importance of genomic medicine, writes Mark. J. Stevens.
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
The Benefits of IT Outsourcing in Life SciencesFrom lightweight ERP work, to break fix services, to infrastructure- how start-up life sciences organizations, or those new to the outsourcing model, are benefiting from the use of IT partners.
Latest:
Don't Be a COVID Copycat: Digital Engagement is Not EnoughEven before COVID-19, over 50% of pharma companies were piloting or using virtual and live remote e-detailing as standard practice. Companies need to go further to have a real impact, writes Rasim Shah.
Latest:
Iraq: Stabilizing a Growing MarketAli Mosawi writes about the misconceptions of Iraq's often inhospitable landscape, the essential role of international expertise in driving growth, and how the sector has adapted to meet the challenges of the COVID-19 pandemic.
Latest:
COVID-19: Testing Biotech's Ingenuity in New WaysStartup biotechs need to ensure that life-changing and potentially lifesaving treatments continue to be developed in in the midst of the COVID-19 pandemic. Ohana Biosciences' Amber Salzman outlines how her company is
Latest:
How to Leverage Pricing Governance to Safeguard the ToplineWhile crucial, product-level brand strategies or launch strategies are not sufficient to ensure the long-term success of a product. Best-in-class companies are set apart by their internal pricing governance, write Stephan Schurz and Dr. Fangting Yu.
Latest:
Making the Most of Social Media (Within FDA’s New Guidelines)Pharmaceutical companies have begun using social media for business needs and promotion, yet have been hesitant to become too engaged since the FDA’s stance on social media activity remained unclear.
Latest:
How Life Sciences Companies Can Promote Greater Medication Adherence During COVID19Life sciences companies have an essential role in partnering with providers to deliver targeted communications about medication efficacy and adherence – not only where COVID-19 is well-established, but alsoin areas of emerging risk.
Latest:
A Sustainable Response to COVID-19Three areas critical to ensuring meaningful long-term action.
Latest:
Drug Development in Wartime: Driving Tomorrow's R&D Decisions with Today's COVID-19 DataThe only way for pharma companies to know where to focus their COVID-19 R&D efforts is for the industry to have access to real-time, real-world evidence of what’s working to keep people alive, write Travis Leonardi and William Kirsh.
Latest:
A Better Path to Payer InsightsPayers have transformed the competitive marketplace, and biopharma companies need to regain their position as the authority on their products. To do this, they must establish new ways to anticipate, identify, and react to payer impressions of relevant evidence as they occur.
Latest:
Is Pharma Too Introspective to be Truly Innovative?Every major pharma company undertakes some form of diversity and inclusion work. However, that doesn’t mean it’s reaching the decision-makers, writes Stephen Frost.
Latest:
Coordinating Data and Analytics Ownership with Payers and ProvidersMatthew Sussman explores strategies for facilitating access to the timely patient data and analysis needed for successful value-based agreements between manufacturers, payer and provider organizations in 2020 and beyond.
Latest:
How to Ride the Data Wave When Launching a New DrugHow exactly do pharma companies account for a gap between their hopes for a new drug and reality? Peter Harbin reports.
